SYNCHRONIZE-CVOT (Recruiting)
A Phase III, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity
- Medicine
- BI 456906
- Population
- ASCVD
- Phase
- III
- Starting year
- 2022